This study identified a genetic locus associated with rhabdomyosarcoma susceptibility in mice and found that specific differentiation markers are linked to the regression of basal cell carcinoma.
June 2010 in “Melanoma research” This study found that LDE225, a novel Smo antagonist, shows potential as a topical treatment for basal cell carcinoma due to its high affinity binding and effective inhibition of tumor growth in preclinical models.
18 citations
,
January 2009 in “Experimental Dermatology” This study proposes that mammalian target of rapamycin (mTOR) may connect various signaling pathways in hair follicle tumor formation, offering a potential unified model for understanding these tumors.
3 citations
,
February 2005 in “Expert Opinion on Investigational Drugs” This review discusses investigational treatments for androgenetic and chemotherapy-induced alopecia and reports no new clinical results, highlighting the need for further research.
February 2026 in “Frontiers in Medicine” In this case report, a three-generation family with Gorlin-Goltz syndrome showed a heterozygous PTCH1 splice-donor variant associated with the disease, and two affected relatives benefited from individualized, side-effect-guided dosing of the drug sonidegib, experiencing regression of basal cell carcinoma lesions.
